MELEMA Pharma GmbH is a recently founded pharmaceutical biotechnology company with a focus on the development of cancer drugs based on natural substances.

The lead product, ME-503 (Aviscumine), is a recombinant protein that has been used in various phase I clinical studies and has recently completed a promising phase II study in patients with refractory metastatic melanoma (Stage IV). This test revealed significant clinical activity for ME-503, which was significantly superior to standard therapy in a historical control group.

In addition: The very good compatibility data from this study confirm corresponding experiences from the Phase I program.

MELEMA Pharma will widely exploit the potential of ME-503 as an immunotherapeutic agent in this and other indications. The company is particularly interested in partnerships in order to accelerate clinical development here.